Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 300

1.

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019.

Winthrop KL, Weinblatt ME, Bathon J, Burmester GR, Mease PJ, Crofford L, Bykerk V, Dougados M, Rosenbaum JT, Mariette X, Sieper J, Melchers F, Cronstein BN, Breedveld FC, Kalden J, Smolen JS, Furst D.

Ann Rheum Dis. 2019 Oct 29. pii: annrheumdis-2019-216151. doi: 10.1136/annrheumdis-2019-216151. [Epub ahead of print]

2.

Georgia Abortion Law and our Commitment to Patients.

Craft JE, Crow MK, Diamond B, Elkon KB, Flood J, Fox DA, Gabriel SE, Gilkeson GS, Hahn BH, Hardin JA, Koopman WJ, Lockshin MD, Salmon JE, Seaman WE, Sergent JS, Uknis AB, Weinblatt ME, Wofsy D.

Arthritis Rheumatol. 2019 Oct 21. doi: 10.1002/art.41143. [Epub ahead of print]

PMID:
31637878
3.

Genetic associations with radiological damage in rheumatoid arthritis: Meta-analysis of seven genome-wide association studies of 2,775 cases.

Traylor M, Knevel R, Cui J, Taylor J, Harm-Jan W, Conaghan PG, Cope AP, Curtis C, Emery P, Newhouse S, Patel H, Steer S, Gregersen P, Shadick NA, Weinblatt ME, Van Der Helm-van Mil A, Barrett JH, Morgan AW, Lewis CM, Scott IC.

PLoS One. 2019 Oct 9;14(10):e0223246. doi: 10.1371/journal.pone.0223246. eCollection 2019.

4.

Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs.

Alemao E, Bao Y, Weinblatt ME, Shadick N.

Arthritis Care Res (Hoboken). 2019 Sep 17. doi: 10.1002/acr.24071. [Epub ahead of print]

PMID:
31529682
5.

Correction: Prevalence and predictors for sustained remission in rheumatoid arthritis.

Sung YK, Yoshida K, Prince FHM, Frits ML, Cho SK, Choe JY, Lee HS, Lee J, Lee SS, Yoo DH, Helfgott SM, Shadick NA, Weinblatt ME, Solomon DH, Bae SC.

PLoS One. 2019 Aug 14;14(8):e0221314. doi: 10.1371/journal.pone.0221314. eCollection 2019.

6.

Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry.

Huang S, He X, Doyle TJ, Zaccardelli A, Marshall AA, Friedlander HM, Blaustein RB, Smith EA, Cui J, Iannaccone CK, Mahmoud TG, Weinblatt ME, Dellaripa PF, Shadick NA, Sparks JA.

Clin Rheumatol. 2019 Dec;38(12):3401-3412. doi: 10.1007/s10067-019-04733-9. Epub 2019 Aug 13.

PMID:
31410660
7.

In Memoriam: Shaun Ruddy, MD, 1935-2019.

Weinblatt ME, Kelley WN.

Arthritis Rheumatol. 2019 Aug;71(8):1215-1216. doi: 10.1002/art.40916. No abstract available.

PMID:
31353873
8.

The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.

Shadick NA, Gerlanc NM, Frits ML, Stolshek BS, Brady BL, Iannaccone C, Collier D, Cui J, Mutebi A, Weinblatt ME.

Clin Rheumatol. 2019 Nov;38(11):3081-3092. doi: 10.1007/s10067-019-04649-4. Epub 2019 Jul 29.

PMID:
31353421
9.

Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis.

Yang N, Huang J, Frits M, Iannaccone C, Weinblatt ME, Rifai N, Shadick N, Bradwin G, Liao KP.

Pract Lab Med. 2019 May 3;16:e00122. doi: 10.1016/j.plabm.2019.e00122. eCollection 2019 Aug.

10.

Association of Changes in Anticitrullinated Protein Antibody Levels With Resource Use and Disease Activity Measures in Rheumatoid Arthritis Patients a US Observational Cohort.

Alemao E, Iannaccone CK, Weinblatt ME, Shadick NA.

Clin Ther. 2019 Jun;41(6):1057-1065.e3. doi: 10.1016/j.clinthera.2019.04.029. Epub 2019 May 23.

PMID:
31130229
11.

Rheumatoid Nodule Formation in the Kidney: A Diagnosis of Exclusion and a Rare Manifestation of Rheumatoid Arthritis Involving the Kidney.

Sekulic M, Weinblatt ME, Rennke HG.

Kidney Int Rep. 2019 Jan 28;4(5):745-748. doi: 10.1016/j.ekir.2019.01.017. eCollection 2019 May. No abstract available.

12.

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39.

Spiliopoulou A, Colombo M, Plant D, Nair N, Cui J, Coenen MJ, Ikari K, Yamanaka H, Saevarsdottir S, Padyukov L, Bridges SL Jr, Kimberly RP, Okada Y, van Riel PLC, Wolbink G, van der Horst-Bruinsma IE, de Vries N, Tak PP, Ohmura K, Canhão H, Guchelaar HJ, Huizinga TW, Criswell LA, Raychaudhuri S, Weinblatt ME, Wilson AG, Mariette X, Isaacs JD, Morgan AW, Pitzalis C, Barton A, McKeigue P.

Ann Rheum Dis. 2019 Aug;78(8):1055-1061. doi: 10.1136/annrheumdis-2018-214877. Epub 2019 Apr 29.

13.

Prevalence and predictors for sustained remission in rheumatoid arthritis.

Sung YK, Yoshida K, Prince FHM, Frits ML, Cho SK, Choe JY, Lee HS, Lee J, Lee SS, Yoo DH, Helfgott SM, Shadick NA, Weinblatt ME, Solomon DH, Bae SC.

PLoS One. 2019 Apr 19;14(4):e0214981. doi: 10.1371/journal.pone.0214981. eCollection 2019. Erratum in: PLoS One. 2019 Aug 14;14(8):e0221314.

14.

Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study.

Sparks JA, He X, Huang J, Fletcher EA, Zaccardelli A, Friedlander HM, Gill RR, Hatabu H, Nishino M, Murphy DJ, Iannaccone CK, Mahmoud TG, Frits ML, Lu B, Rosas IO, Dellaripa PF, Weinblatt ME, Karlson EW, Shadick NA, Doyle TJ.

Arthritis Rheumatol. 2019 Sep;71(9):1472-1482. doi: 10.1002/art.40904. Epub 2019 Aug 4.

PMID:
30951251
15.

Incidence and predictors of dyspnea on exertion in a prospective cohort of patients with rheumatoid arthritis.

Sparks JA, Doyle TJ, He X, Pan B, Iannaccone C, Frits ML, Dellaripa PF, Rosas IO, Lu B, Weinblatt ME, Shadick NA, Karlson EW.

ACR Open Rheumatol. 2019 Mar;1(1):4-15. doi: 10.1002/acr2.1001. Epub 2019 Mar 15.

PMID:
30923795
16.

Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis.

Bay-Jensen AC, Platt A, Jenkins MA, Weinblatt ME, Byrjalsen I, Musa K, Genovese MC, Karsdal MA.

BMC Rheumatol. 2019 Jan 31;3:3. doi: 10.1186/s41927-019-0052-0. eCollection 2019.

17.

Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept.

Dervieux T, Kremer JM, Weinblatt ME.

Ann Rheum Dis. 2019 Sep;78(9):1285-1286. doi: 10.1136/annrheumdis-2018-214860. Epub 2019 Mar 18. No abstract available.

18.

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.

Winthrop KL, Weinblatt ME, Crow MK, Burmester GR, Mease PJ, So AK, Bykerk V, Van Vollenhoven RF, Dougados M, Kay J, Mariette X, Sieper J, Melchers F, Cronstein BN, Shevach E, Breedfeld FC, Kalden J, Smolen JS, Furst DE.

Ann Rheum Dis. 2019 Jul;78(7):872-878. doi: 10.1136/annrheumdis-2018-214280. Epub 2019 Feb 2. Review.

PMID:
30712015
19.

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.

Taylor PC, Weinblatt ME, Burmester GR, Rooney TP, Witt S, Walls CD, Issa M, Salinas CA, Saifan C, Zhang X, Cardoso A, González-Gay MA, Takeuchi T.

Arthritis Rheumatol. 2019 Jul;71(7):1042-1055. doi: 10.1002/art.40841. Epub 2019 May 25.

20.

Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis.

Curtis JR, Flake DD, Weinblatt ME, Shadick NA, Østergaard M, Hetland ML, Brahe CH, Hwang YG, Furst DE, Strand V, Etzel CJ, Pappas DA, Wang X, Hwang CC, Sasso EH, Gutin A, Hitraya E, Lanchbury JS.

Rheumatology (Oxford). 2019 May 1;58(5):874-883. doi: 10.1093/rheumatology/key367.

21.

Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study.

Desai RJ, Pawar A, Weinblatt ME, Kim SC.

Arthritis Rheumatol. 2019 Jun;71(6):892-900. doi: 10.1002/art.40798. Epub 2019 Apr 29.

PMID:
30552833
22.

Mixed-effects association of single cells identifies an expanded effector CD4+ T cell subset in rheumatoid arthritis.

Fonseka CY, Rao DA, Teslovich NC, Korsunsky I, Hannes SK, Slowikowski K, Gurish MF, Donlin LT, Lederer JA, Weinblatt ME, Massarotti EM, Coblyn JS, Helfgott SM, Todd DJ, Bykerk VP, Karlson EW, Ermann J, Lee YC, Brenner MB, Raychaudhuri S.

Sci Transl Med. 2018 Oct 17;10(463). pii: eaaq0305. doi: 10.1126/scitranslmed.aaq0305.

23.

Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis.

Alemao E, Al MJ, Boonen AA, Stevenson MD, Verstappen SMM, Michaud K, Weinblatt ME, Rutten-van Mölken MPMH.

PLoS One. 2018 Oct 5;13(10):e0205013. doi: 10.1371/journal.pone.0205013. eCollection 2018.

24.

Transient Elastography for Monitoring for Hepatotoxicity in Rheumatoid Arthritis Patients on Long-term Methotrexate.

Wade SD, Yoshida EM, Carruthers MN, Weinblatt ME.

J Clin Rheumatol. 2018 Aug 13. doi: 10.1097/RHU.0000000000000885. [Epub ahead of print] No abstract available.

PMID:
30106792
25.

Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis.

Genovese MC, Weinblatt ME, Mease PJ, Aelion JA, Peloso PM, Chen K, Li Y, Liu J, Othman AA, Khatri A, Mansikka HT, Leszczynski P.

Rheumatology (Oxford). 2018 Nov 1;57(11):1972-1981. doi: 10.1093/rheumatology/key173.

PMID:
30032191
26.

Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate.

Mease PJ, Genovese MC, Weinblatt ME, Peloso PM, Chen K, Othman AA, Li Y, Mansikka HT, Khatri A, Wishart N, Liu J.

Arthritis Rheumatol. 2018 Nov;70(11):1778-1789. doi: 10.1002/art.40579.

27.

ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double-Blind Study.

Genovese MC, Weinblatt ME, Aelion JA, Mansikka HT, Peloso PM, Chen K, Li Y, Othman AA, Khatri A, Khan NS, Padley RJ.

Arthritis Rheumatol. 2018 Nov;70(11):1710-1720. doi: 10.1002/art.40580. Epub 2018 Oct 10.

28.

Methotrexate: who would have predicted its importance in rheumatoid arthritis?

Weinblatt ME.

Arthritis Res Ther. 2018 May 30;20(1):103. doi: 10.1186/s13075-018-1599-7. No abstract available.

29.

Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis.

Kjelgaard-Petersen CF, Platt A, Braddock M, Jenkins MA, Musa K, Graham E, Gantzel T, Slynn G, Weinblatt ME, Karsdal MA, Thudium CS, Bay-Jensen AC.

Arthritis Rheumatol. 2018 Sep;70(9):1419-1428. doi: 10.1002/art.40527. Epub 2018 Jul 24.

30.

Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids.

Hu Y, Carman JA, Holloway D, Kansal S, Fan L, Goldstine C, Lee D, Somerville JE, Latek R, Townsend R, Johnsen A, Connolly S, Bandyopadhyay S, Shadick N, Weinblatt ME, Furie R, Nadler SG.

Arthritis Rheumatol. 2018 Aug;70(8):1331-1342. doi: 10.1002/art.40476. Epub 2018 Jul 12.

31.

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.

Weinblatt ME, Baranauskaite A, Dokoupilova E, Zielinska A, Jaworski J, Racewicz A, Pileckyte M, Jedrychowicz-Rosiak K, Baek I, Ghil J.

Arthritis Rheumatol. 2018 Jun;70(6):832-840. doi: 10.1002/art.40444. Epub 2018 Apr 24.

32.

Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis.

Fleischmann R, Wollenhaupt J, Cohen S, Wang L, Fan H, Bandi V, Andrews J, Takiya L, Bananis E, Weinblatt ME.

Rheumatol Ther. 2018 Jun;5(1):203-214. doi: 10.1007/s40744-018-0093-7. Epub 2018 Feb 7.

33.

A Development and Feasibility Study of a Peer Support Telephone Program in Rheumatoid Arthritis.

Shadick NA, Zibit MJ, Iannaccone CK, Thrower R, Sowell NF, Weinblatt ME, Solomon DH, Cui J.

J Clin Rheumatol. 2018 Sep;24(6):346-349. doi: 10.1097/RHU.0000000000000661. No abstract available.

34.

Association of anti-cyclic citrullinated protein antibodies, erosions, and rheumatoid factor with disease activity and work productivity: A patient registry study.

Alemao E, Guo Z, Frits ML, Iannaccone CK, Shadick NA, Weinblatt ME.

Semin Arthritis Rheum. 2018 Apr;47(5):630-638. doi: 10.1016/j.semarthrit.2017.10.009. Epub 2017 Oct 13.

PMID:
29241640
35.

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.

Weinblatt ME, Baranauskaite A, Niebrzydowski J, Dokoupilova E, Zielinska A, Jaworski J, Racewicz A, Pileckyte M, Jedrychowicz-Rosiak K, Cheong SY, Ghil J.

Arthritis Rheumatol. 2018 Jan;70(1):40-48. doi: 10.1002/art.40336. Epub 2017 Nov 21.

36.

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.

Weinblatt ME, McInnes IB, Kremer JM, Miranda P, Vencovsky J, Guo X, White WI, Ryan PC, Godwood A, Albulescu M, Close D, Burmester GR.

Arthritis Rheumatol. 2018 Jan;70(1):49-59. doi: 10.1002/art.40323.

37.

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.

Keystone EC, Taylor PC, Tanaka Y, Gaich C, DeLozier AM, Dudek A, Zamora JV, Cobos JAC, Rooney T, Bono S, Arora V, Linetzky B, Weinblatt ME.

Ann Rheum Dis. 2017 Nov;76(11):1853-1861. doi: 10.1136/annrheumdis-2017-211259. Epub 2017 Aug 10.

38.

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.

Weinblatt ME, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, VanLunen B, Ecoffet C, Cioffi C, Emery P.

Arthritis Rheumatol. 2017 Oct;69(10):1937-1948. doi: 10.1002/art.40196. Epub 2017 Sep 12.

39.

Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement.

Solomon DH, Shadick NA, Weinblatt ME, Zak A, Frits M, Franklin JM.

Arthritis Res Ther. 2017 Jun 13;19(1):130. doi: 10.1186/s13075-017-1330-0.

40.

Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate.

Kremer JM, Weinblatt ME.

Ann Rheum Dis. 2018 Jan;77(1):e4. doi: 10.1136/annrheumdis-2017-211632. Epub 2017 Jun 8. No abstract available.

PMID:
28596184
41.

Clinical patient registry recruitment and retention: a survey of patients in two chronic disease registries.

Solomon DH, Shadick NA, Weinblatt ME, Frits M, Iannaccone C, Zak A, Korzenik JR.

BMC Med Res Methodol. 2017 Apr 17;17(1):59. doi: 10.1186/s12874-017-0343-3.

42.

Sirolimus as an Effective Agent in the Treatment of Immune Thrombocytopenia (ITP) and Evans Syndrome (ES): A Single Institution's Experience.

Jasinski S, Weinblatt ME, Glasser CL.

J Pediatr Hematol Oncol. 2017 Aug;39(6):420-424. doi: 10.1097/MPH.0000000000000818.

PMID:
28267088
43.

Diet and Rheumatoid Arthritis Symptoms: Survey Results From a Rheumatoid Arthritis Registry.

Tedeschi SK, Frits M, Cui J, Zhang ZZ, Mahmoud T, Iannaccone C, Lin TC, Yoshida K, Weinblatt ME, Shadick NA, Solomon DH.

Arthritis Care Res (Hoboken). 2017 Dec;69(12):1920-1925. doi: 10.1002/acr.23225.

44.

A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.

Burmester GR, McInnes IB, Kremer J, Miranda P, Korkosz M, Vencovsky J, Rubbert-Roth A, Mysler E, Sleeman MA, Godwood A, Sinibaldi D, Guo X, White WI, Wang B, Wu CY, Ryan PC, Close D, Weinblatt ME; EARTH EXPLORER 1 study investigators.

Ann Rheum Dis. 2017 Jun;76(6):1020-1030. doi: 10.1136/annrheumdis-2016-210624. Epub 2017 Feb 17.

45.

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.

Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y.

N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345.

46.

Fibromyalgia and the Prediction of Two-Year Changes in Functional Status in Rheumatoid Arthritis Patients.

Kim H, Cui J, Frits M, Iannaccone C, Coblyn J, Shadick NA, Weinblatt ME, Lee YC.

Arthritis Care Res (Hoboken). 2017 Dec;69(12):1871-1877. doi: 10.1002/acr.23216. Epub 2017 Nov 14.

47.

Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis.

Rao DA, Gurish MF, Marshall JL, Slowikowski K, Fonseka CY, Liu Y, Donlin LT, Henderson LA, Wei K, Mizoguchi F, Teslovich NC, Weinblatt ME, Massarotti EM, Coblyn JS, Helfgott SM, Lee YC, Todd DJ, Bykerk VP, Goodman SM, Pernis AB, Ivashkiv LB, Karlson EW, Nigrovic PA, Filer A, Buckley CD, Lederer JA, Raychaudhuri S, Brenner MB.

Nature. 2017 Feb 1;542(7639):110-114. doi: 10.1038/nature20810.

48.

Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers.

Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, Heijde Dv, Vollenhoven Rv, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME.

Ann Rheum Dis. 2016 Oct;75(10):e69. doi: 10.1136/annrheumdis-2016-210083. Epub 2016 Aug 12. No abstract available.

49.

Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.

Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein S, Camp HS, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S.

Arthritis Rheumatol. 2016 Dec;68(12):2857-2866. doi: 10.1002/art.39808.

50.

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.

Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME.

Ann Rheum Dis. 2017 Jan;76(1):96-104. doi: 10.1136/annrheumdis-2015-209057. Epub 2016 May 10.

Supplemental Content

Loading ...
Support Center